Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis

Pharmacoepidemiology and Drug Safety
Tsung YuMilo A Puhan

Abstract

Synthesizing evidence from comparative effectiveness trials can be difficult because multiple outcomes of different importance are to be considered. The goal of this study was to demonstrate an approach to conducting quantitative benefit-harm assessment that considers patient preferences. We conducted a benefit-harm assessment using data from the Multicenter Uveitis Steroid Treatment Trial that compared corticosteroid implant versus systemic corticosteroids and immunosuppression in non-infectious intermediate, posterior, and panuveitis. We focused on clinical outcomes considered important to patients, including visual acuity, development of cataracts/glaucoma, need for eye surgery, prescription-requiring hypertension, hyperlipidemia, and infections. Patient preferences elicited in a recent survey were then incorporated into our assessment of the benefit-harm balance. Benefit-harm metrics were calculated for each time point that summarized the numbers of outcomes, caused or prevented by implant therapy versus systemic therapy if 1000 patients were treated. The benefit-harm metric was -129 (95% confidence interval: -242 to -14), -317 (-436 to -196), -390 (-514 to -264), and -526 (-687 to -368) at 6, 12, 18, and 24 months follow u...Continue Reading

Associated Clinical Trials

References

Nov 5, 1999·Journal of the National Cancer Institute·M H GailV Vogel
May 11, 2007·Ophthalmology·Nancy K JanzUNKNOWN Collaborative Initial Glaucoma Treatment Study
Aug 8, 2009·Pharmacoepidemiology and Drug Safety·Stephen R WisniewskiAndrei Pikalov
Aug 12, 2009·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN National Institute of Neurological Disorders, National Institutes of Health
Oct 6, 2009·Journal of Clinical Epidemiology·Maarten BoersPeter Tugwell
Jan 26, 2010·American Journal of Ophthalmology·UNKNOWN Multicenter Uveitis Steroid Treatment Trial Research GroupElizabeth A Sugar
Feb 24, 2010·Expert Opinion on Drug Safety·Daniele Ouellet
Apr 24, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeff J GuoDennis W Raisch
Aug 12, 2010·JAMA : the Journal of the American Medical Association·Helena Chmura Kraemer, Ellen Frank
Jan 26, 2011·International Journal of Technology Assessment in Health Care·Marie-Pierre GagnonFrance Légaré
Apr 19, 2012·JAMA : the Journal of the American Medical Association·UNKNOWN Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI)
Nov 21, 2012·BMC Medical Research Methodology·Milo A PuhanCynthia M Boyd
Dec 18, 2013·Investigative Ophthalmology & Visual Science·Ronald Klein, Barbara E K Klein
Dec 19, 2013·Thorax·Tsung YuMilo A Puhan
May 14, 2014·Pharmacoepidemiology and Drug Safety·Shahrul Mt-IsaUNKNOWN IMI-PROTECT benefit-risk participants
Oct 27, 2015·Investigative Ophthalmology & Visual Science·Tsung YuMilo A Puhan

❮ Previous
Next ❯

Citations

Aug 17, 2018·Current Medical Research and Opinion·J Bradford RiceWinnie W Nelson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.